Scoop
Automating regulatory submissions for life sciences
Scoop is a business in b2b based in San Francisco, CA, USA.
Profile
We’re building AI agents that speed up drug trials by automating the manual consolidation and document prep required for every IND submission. Today, biotechs spend months stitching together reports from contractors and internal teams just to file and get to their first-in-human trial.
Within the b2b space, the company focuses on its core offering rather than a broad product line.
The company is recorded as being based in San Francisco, CA, USA.
The company is listed at the Fall 2025 stage of development.
The company reports a headcount in the 2 range.
Directory analysis
Scoop is a San Francisco‑based B2B startup that builds AI agents to automate the preparation and consolidation of documents required for Investigational New Drug (IND) submissions in the life‑sciences sector. By streamlining these regulatory processes, the company aims to reduce the time biotechs spend compiling reports from contractors and internal teams, thereby accelerating the path to first‑in‑human trials.
Positioning: Scoop operates in a niche yet critical area of the drug development pipeline, targeting a market that traditionally relies on manual, time‑consuming documentation workflows. Its focus on AI‑driven automation positions it as a potential disruptor for regulatory compliance within the biotech industry.
Note: Scoop specializes in automating IND submission workflows for biotech companies.
Auto-generated directory analysis from public data · updated 8 Oct 2026. Informational only, not investment advice.
| Sector | B2B |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Fall 2025 |
Website: scooplabs.ai
Browse related
Create a free account